IMOCOLIBOV

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Inactivated e.coli (antigen k99), Inactivated e.coli (antigen y), Inactivated e.coli (antigen 31a), Inactivated e.coli serotype 09, Inactivated e.coli serotype 08, Inactivated e.coli serotype 015, Inactivated e.coli serotype 078, Inactivated e.coli serotype 0101, Inactivated e.coli serotype 00117

から入手可能:

Merial Animal Health Limited

ATCコード:

QI02AC

INN（国際名）:

Inactivated e.coli (antigen k99), Inactivated e.coli (antigen y), Inactivated e.coli (antigen 31a), Inactivated e.coli serotype

投薬量:

percent

医薬品形態:

Suspension for injection

処方タイプ:

LM: Licensed Merchant as defined in relevant national legislation

治療群:

Cattle, Sheep

治療領域:

Inactivated bacterial vaccines and antisera QI04AC Inactivated bacterial vaccines and antisera

適応症:

Immunological - Inactivated Vaccine

認証ステータス:

Authorised

承認日:

2003-08-06

製品の特徴

IRISH MEDICINES BOARD ACT 1995
EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (NO. 2) REGULATIONS 2007
(S.I. NO. 786 OF 2007)
VPA:
10857/033/001
Case No: 7004886
The Irish Medicines Board in exercise of the powers conferred on it by
Animal Remedies (No. 2) Regulations (S.I. No. 786 of 2007) hereby
grants to:
MERIAL ANIMAL HEALTH LIMITED
SANDRINGHAM HOUSE
,
SANDRINGHAM AVENUE, HARLOW BUSINESS PARK, HARLOW
,
ESSEX CM19 5TG
,
UNITED KINGDOM
an authorisation, subject to the provisions of the said Regulations
and the general conditions of the attached authorisation, in respect
of the
Veterinary Medicinal Product:
IMOCOLIBOV
The particulars of which are set out in Part 1 and Part 2 of the said
Schedule. The authorisation is also subject to any special conditions
as may
be specified in the said Schedule.
The authorisation,unless revoked, shall continue in force from
22/09/2008
.
Signed on behalf of the Irish Medicines Board
________________
A person authorised in that behalf by the said Board.
(NOTE: This authorisation replaces any previous authorisation in
respect of this product which is now null and void.)
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_3_
_/_
_0_
_9_
_/_
_2_
_0_
_0_
_8_
_C_
_R_
_N_
_ _
_7_
_0_
_0_
_4_
_8_
_8_
_6_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
IMOCOLIBOV
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of vaccine contains_ E. coli_ somatic serotypes 09, 08, 015,
078, 0101, 0117, expressi